艾司西酞普兰与帕罗西汀治疗抑郁症伴焦虑症状对照研究

目的 探讨艾司西酞普兰与帕罗西汀治疗抑郁症伴焦虑症状的临床疗效及安全性.方法将52例抑郁症伴焦虑症状患者随机分为两组,每组26例,研究组口服艾司西酞普兰治疗,对照组口服帕罗西汀治疗,观察6周.于治疗前及治疗1周、2周、4周、6周末采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组汉密顿抑郁量表总分及焦虑/躯体化因子分均较治疗前显著下降(P<0.01),研究组治疗2周末均较对照组下降更显著(t=3.21,2.52,P<0.01);治疗6周末,研究组总有效率88.46%,对照组为84.62%,两组差异无显著性(X2=0.118,P>0.05).两组不良反应均轻微.结论 艾司西酞普兰与帕罗西汀治疗抑郁症伴焦虑症状疗效显著,总体疗效相当,安全性高,依从件好,但艾司西酞普兰起效更快,可作为治疗抑郁症伴焦虑症状的首选药物.

A control study of escitalopram vs.paroxetine in the treatment of depression accompanied with anxiety symptoms

Objective To explore the clinical efficacy and safety of escitalopram vs. paroxetine in the treatment of depression with anxiety symptoms （DAS）. Methods Fifty-two DAS patients were randomly divided into research group （n=26）took orally escitalopram and control group （n=26）did paroxetine for 6 weeks. Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD）and adverse reactions with the Treatment Emergent Symptom Scale （TESS）before and at the end of the 1st ,2nd ,4th ,and 6th week treatment. Results After treatment, the total, anxiety and somatization scores of the HAMD of both groups lowered more significantly compared with pretreatment（P〈0.01）, so did in the research than in the control group at the end of the 2nd week （t=3.21,2.52,P〈0.01） ;at the end of the the 6th week, the total effective rates were respectively 88.5 %in the research and 84.6%in the control group, which showed no significant difference （X^2 =0. 118,P〉0.05）. Adverse reactions of both groups were mild. Conclusion Both escitalopram and paroxetine have same and significant efficacy, high safety and good compliance in DAS, but the former takes effect more rapidly and can be used as drug of choice for DAS.